References
- Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11(11):1036-47
- Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009;374(9700):1512-20
- Herrlinger U, Schabet M, Brugger W, et al. Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002;51(2):247-52
- Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21(24):4489-95
- Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18(17):3144-50
- Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non–AIDS–related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group phase II trial. 20962. J Clin Oncol 2003;21(24):4483-8
- DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93–10. J Clin Oncol 2002;20(24):4643-8
- Korfel A, Martus P, Nowrousian MR, et al. German Primary Central Nervous System Lymphoma Study Group (G–PCNSL–SG). Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br J Haematol 2005;128(2):177-83
- Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101(2):466-8
- Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 2013;31(31):3971-9
- Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 2014;83(3):235-9
- Bleyer WA, Poplack DG, Simon RM. “Concentration x time” methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978;51(5):835-42
- Pels H, Juergens A, Glasmacher A, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 2009;91(3):299-305
- Korfel A, Thiel E, Martus P, et al. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 2015;84(12):1242-8
- Doolittle ND, Korfel A, Lubow M, et al. Long-term cognitive function, neuroimaging and quality of life in primary CNS lymphoma. Neurology 2013;81(1):84-92
- Rubenstein J, His E, Johnson J, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013;31(25):3061-8
- Illerhaus G, Fritsch K, Egerer G, et al. Sequential high dose immuno-chemotherapy followed by autologous peripheral blood stem cell transplantation for patients with untreated primary central nervous system lymphoma - a multicentre study by the collaborative PCNSL study group freiburg [abstract 302]. ASH Meeting; 8 November 2012; Atlanta; 2012
- Omuro A, Correa D, DeAngelis L, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015;125(9):1403-10
- Kiewe P, Martus P, Thiel E, et al. Phase II trial of temsirolimus for relapsed/refractory primary central nervous system lymphoma (PCNSL). Oncol Res Treat 2014;37(Suppl):5
- Ponzoni M, Issa S, Batchelor TT, et al. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol 2014;25(2):316-22